AR085305A1 - USE OF TERIFLUNOMIDE FOR THE TREATMENT OF COGNITIVE DETERIORATION - Google Patents

USE OF TERIFLUNOMIDE FOR THE TREATMENT OF COGNITIVE DETERIORATION

Info

Publication number
AR085305A1
AR085305A1 ARP120100576A ARP120100576A AR085305A1 AR 085305 A1 AR085305 A1 AR 085305A1 AR P120100576 A ARP120100576 A AR P120100576A AR P120100576 A ARP120100576 A AR P120100576A AR 085305 A1 AR085305 A1 AR 085305A1
Authority
AR
Argentina
Prior art keywords
teriflunomide
treatment
cognitive deterioration
patient
cognitive
Prior art date
Application number
ARP120100576A
Other languages
Spanish (es)
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of AR085305A1 publication Critical patent/AR085305A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La presente se refiere al uso de teriflunomida para tratar el deterioro cognitivo en un paciente que lo necesita, en particular en un paciente que tiene esclerosis múltiple.This refers to the use of teriflunomide to treat cognitive impairment in a patient in need, particularly in a patient who has multiple sclerosis.

ARP120100576A 2011-02-24 2012-02-22 USE OF TERIFLUNOMIDE FOR THE TREATMENT OF COGNITIVE DETERIORATION AR085305A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161446106P 2011-02-24 2011-02-24

Publications (1)

Publication Number Publication Date
AR085305A1 true AR085305A1 (en) 2013-09-18

Family

ID=45809686

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100576A AR085305A1 (en) 2011-02-24 2012-02-22 USE OF TERIFLUNOMIDE FOR THE TREATMENT OF COGNITIVE DETERIORATION

Country Status (4)

Country Link
AR (1) AR085305A1 (en)
TW (1) TW201249429A (en)
UY (1) UY33922A (en)
WO (1) WO2012116128A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Also Published As

Publication number Publication date
WO2012116128A1 (en) 2012-08-30
UY33922A (en) 2012-09-28
TW201249429A (en) 2012-12-16

Similar Documents

Publication Publication Date Title
CL2021000008A1 (en) Use of a Heparinoid for Cancer Treatment (Divisional Application No. 201403017)
UY34201A (en) AZAINDOL COMPOUNDS AND METHODS FOR HIV TREATMENT.
TR201813877T4 (en) COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
UY34750A (en) ? COMPOUNDS FOR HIV TREATMENT, COMPOSITIONS, PREPARATION METHODS, INTERMEDIARIES AND THERAPEUTIC METHODS ?.
GT201400033A (en) SUBSTITUTED RINGED PYRIMIDINES AND USE OF THE SAME
CL2012003385A1 (en) Incontinence treatment.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CU20120161A7 (en) 5-FLUORO-1H-SUBSTITUTED PIRAZOLOPIRIDINS
AR089993A1 (en) PEPTIDOMIMETIC MACROCICLES
CR20130550A (en) CYCLOPROPILAMINS AS INHIBITORS OF DEMETHYLASE 1 SPECIFIC TO LISINA
UY34566A (en) 1,4? DIHYDROPIRIMIDINES 4.4? DISUSTITUTED AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
EA201400178A1 (en) BREAST CANCER TREATMENT
EA201490559A1 (en) COMPOSITION FOR THE TREATMENT OF Fistula
UY34467A (en) PROCEDURE FOR THE PREPARATION OF REPLACED 5-FLUORO-1H-PIRAZOLOPIRIDINAS
CL2015003343A1 (en) Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images.
CL2016001578A1 (en) Piperidinyltetrahydroquinolines substituted and their use as antagonists of alpha-2c adenoreceptors.
CR20140400A (en) COMBINED THERAPY FOR THE TREATMENT OF OVARIO CANCER
CO7160080A2 (en) Lipid compositions of racecadot
EA201590503A1 (en) ALPHA-1-Microglobulin for use in the treatment of diseases associated with mitochondria
CO6741197A2 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
PE20150167A1 (en) (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL
ECSP16061208A (en) QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS
UY35328A (en) TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
AR088764A1 (en) METHODS FOR THE TREATMENT OF A SENSORY-MOTOR IMPEDIMENT RELATED TO THE CEREBROVASCULAR ACCIDENT WITH THE USE OF AMINOPIRIDINS
CR20110023A (en) NIFURTIMOX FOR THE TREATMENT OF DISEASES CAUSED BY TRICHOMONADIDA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal